Home » Stocks » NTLA

Intellia Therapeutics, Inc. (NTLA)

Stock Price: $81.89 USD -1.41 (-1.69%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $81.90 +0.01 (0.01%) Jan 15, 7:53 PM
Market Cap 5.29B
Revenue (ttm) 62.34M
Net Income (ttm) -120.32M
Shares Out 58.75M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $81.89
Previous Close $83.30
Change ($) -1.41
Change (%) -1.69%
Day's Open 83.87
Day's Range 81.59 - 92.00
Day's Volume 2,622,548
52-Week Range 9.44 - 92.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 2 days ago

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...

Other stocks mentioned: BEAM, CLLS, CLXT, CRSP, EDIT, SGMO
Forbes - 6 days ago

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible fo...

Other stocks mentioned: EDIT, CRSP
GuruFocus - 1 week ago

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Other stocks mentioned: CRSP, EDIT
The Dog of Wall Street - 1 week ago

We all know about the red-hot sectors like electric vehicles, SPAC IPOs, and cloud based software, but the real investors know that the next industry to truly take off is in biotech, specifica...

Zacks Investment Research - 1 week ago

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR tech...

The Motley Fool - 1 week ago

Investors are looking forward to what could be a great year for the biotechnology company.

Zacks Investment Research - 1 week ago

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Other stocks mentioned: CRSP, EDIT
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...

Zacks Investment Research - 1 week ago

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: CBAY, EDIT, MRNS, VRTX
The Motley Fool - 2 weeks ago

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Other stocks mentioned: CRSP, EDIT
Zacks Investment Research - 2 weeks ago

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: FATE, MRNA, MRSN, RARE
Seeking Alpha - 3 weeks ago

Intellia is overshadowed a bit by its cousins Editas & CRISPR Therapeutics, however Intellia has a rich pipeline that looks to be focused on a few opportunities outside of its competition. The...

Investors Business Daily - 3 weeks ago

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Other stocks mentioned: EDIT, QURE
GlobeNewsWire - 1 month ago

Demonstrates modularity of Intellia's in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy

Zacks Investment Research - 1 month ago

In the Century of Biology, it pays to own the future of curing disease at the root.

Other stocks mentioned: CRSP, EDIT, SGMO, VRTX
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting new preclinical data in support of NTLA-5001, the company's wholly owned Wilms' Tum...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...

Zacks Investment Research - 1 month ago

Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...

GlobeNewsWire - 2 months ago

Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients

GlobeNewsWire - 2 months ago

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression

Seeking Alpha - 2 months ago

Intellia Therapeutics, Inc.'s (NTLA) CEO John Leonard on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...

GlobeNewsWire - 2 months ago

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry fo...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...

GlobeNewsWire - 3 months ago

In Vivo g ene k nockout and i nsertion data to be presented at O TS Annual Meeting  highlight modularity of Intellia’s platform and potential for variety of single-course therapies , ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...

Seeking Alpha - 3 months ago

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a preclinical-stage genome editing company focusing on developing novel therapeutics using the genome-editing process known as CRISPR/Cas9.

Zacks Investment Research - 4 months ago

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

Other stocks mentioned: CRSP, EDIT, SGMO, VRTX
GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...

Seeking Alpha - 5 months ago

Intellia Therapeutics (NTLA) CEO John Leonard on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

Intellia Therapeutics (NTLA) CEO Ernest Garcia on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 11.59% and 72.13%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

Zacks Investment Research - 5 months ago

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

The Motley Fool - 6 months ago

Could this promising gene-editing company make you rich?

The Motley Fool - 6 months ago

Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?

Other stocks mentioned: EDIT
GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

Zacks Investment Research - 7 months ago

Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

The Motley Fool - 7 months ago

Which gene editing stock wins this matchup?

Other stocks mentioned: CRSP
GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...

The Motley Fool - 7 months ago

An existing partner is doubling down on the gene editing platform.

Market Watch - 7 months ago

Shares of Regeneron Pharmaceuticals Inc. REGN, +5.98% were down 0.5% in premarket trading on Monday after the company said it had expanded a collaboration with Intellia Therapeutics Inc.

Other stocks mentioned: REGN
Investors Business Daily - 7 months ago

Intellia Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Ca...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 t...

About NTLA

Intellia Therapeutics, a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2016
CEO
John Leonard
Employees
270
Stock Exchange
NASDAQ
Ticker Symbol
NTLA
Full Company Profile

Financial Performance

In 2019, NTLA's revenue was $43.10 million, an increase of 41.63% compared to the previous year's $30.43 million. Losses were -$99.53 million, 16.6% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for NTLA is 66.88, which is a decrease of -18.33% from the latest price.

Price Target
$66.88
(-18.33% downside)